ID

26895

Description

Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02; ODM derived from: https://clinicaltrials.gov/show/NCT00963417

Lien

https://clinicaltrials.gov/show/NCT00963417

Mots-clés

Versions (1)
  1. 28/10/2017 28/10/2017 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

28 octobre 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT00963417

Anglais

Eligibility Breast Cancer NCT00963417

1 Formulaires  
Criteria
Description

Criteria

patient must be eligible and enrolled in the text-2 trial prior to enrolling in text-bone
Description

Study Subject Participation Status | Clinical Trial Specified

Type de données

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0008976
UMLS CUI [2,2]
C0205369
serial bone marrow density (bmd) measurements must be taken within the same institution
Description

Bone Mineral Density Test Series

Type de données

boolean

Alias
UMLS CUI [1,1]
C0177804
UMLS CUI [1,2]
C0205549
hormone receptor positive
Description

Hormone Receptor Positive

Type de données

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C1446409
patient characteristics:
Description

Client Characteristics

Type de données

boolean

Alias
UMLS CUI [1]
C0815172
see disease characteristics
Description

ID.5

Type de données

boolean

premenopausal
Description

Premenopausal state

Type de données

boolean

Alias
UMLS CUI [1]
C0232969
no bone fracture in the past 6 months that, in the investigator's judgement, could be related to bone fragility
Description

Exclusion | Bone fracture Relationship Bone fragility

Type de données

boolean

Alias
UMLS CUI [1]
C2828389
UMLS CUI [2,1]
C0016658
UMLS CUI [2,2]
C0439849
UMLS CUI [2,3]
C1390474
no clinical or biochemical malabsorption syndrome, known vitamin d deficiency, active hyper- or hypoparathyroidism, or paget's disease
Description

Exclusion Criteria | Malabsorption Syndrome Biochemical | Vitamin D Deficiency | Hyperparathyroidism | Hypoparathyroidism | Paget's disease

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C0024523
UMLS CUI [2,2]
C0205474
UMLS CUI [3]
C0042870
UMLS CUI [4]
C0020502
UMLS CUI [5]
C0020626
UMLS CUI [6]
C0029401
no uncontrolled thyroid disease, cushing disease, or other pituitary diseases
Description

Exclusion Criteria | Thyroid Disease Uncontrolled | Cushing's disease | Pituitary Diseases

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2,1]
C0040128
UMLS CUI [2,2]
C0205318
UMLS CUI [3]
C0221406
UMLS CUI [4]
C0032002
no other bone disease (including osteomalacia or osteogenesis imperfecta)
Description

Exclusion Criteria | Bone Diseases | Osteomalacia | Osteogenesis Imperfecta

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0005940
UMLS CUI [3]
C0029442
UMLS CUI [4]
C0029434
prior concurrent therapy:
Description

Therapeutic procedure

Type de données

boolean

Alias
UMLS CUI [1]
C0087111
see disease characteristics
Description

ID.12

Type de données

boolean

at least 6 months since prior and no concurrent bisphosphonate therapy (or other bone therapies such as pth or strontium)
Description

Exclusion Criteria | Diphosphonates | Bone disorder therapy | Parathyroid hormone therapy | Strontium

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0012544
UMLS CUI [3]
C0872270
UMLS CUI [4]
C3839506
UMLS CUI [5]
C0038467
at least 6 months since prior glucocorticoid (> 5 mg prednisone or equivalent) for > 1 month
Description

Glucocorticoids | Prednisone Dose | Equivalent

Type de données

boolean

Alias
UMLS CUI [1]
C0017710
UMLS CUI [2,1]
C0032952
UMLS CUI [2,2]
C0178602
UMLS CUI [3]
C0205163
at least 12 months since prior anticonvulsants
Description

Anticonvulsants

Type de données

boolean

Alias
UMLS CUI [1]
C0003286
Retour au début de la page

Similar models

Eligibility Breast Cancer NCT00963417

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Study Subject Participation Status | Clinical Trial Specified
Item
patient must be eligible and enrolled in the text-2 trial prior to enrolling in text-bone
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2,1])
C0205369 (UMLS CUI [2,2])
Bone Mineral Density Test Series
Item
serial bone marrow density (bmd) measurements must be taken within the same institution
boolean
C0177804 (UMLS CUI [1,1])
C0205549 (UMLS CUI [1,2])
Hormone Receptor Positive
Item
hormone receptor positive
boolean
C0019929 (UMLS CUI [1,1])
C1446409 (UMLS CUI [1,2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
ID.5
Item
see disease characteristics
boolean
Premenopausal state
Item
premenopausal
boolean
C0232969 (UMLS CUI [1])
Exclusion | Bone fracture Relationship Bone fragility
Item
no bone fracture in the past 6 months that, in the investigator's judgement, could be related to bone fragility
boolean
C2828389 (UMLS CUI [1])
C0016658 (UMLS CUI [2,1])
C0439849 (UMLS CUI [2,2])
C1390474 (UMLS CUI [2,3])
Exclusion Criteria | Malabsorption Syndrome Biochemical | Vitamin D Deficiency | Hyperparathyroidism | Hypoparathyroidism | Paget's disease
Item
no clinical or biochemical malabsorption syndrome, known vitamin d deficiency, active hyper- or hypoparathyroidism, or paget's disease
boolean
C0680251 (UMLS CUI [1])
C0024523 (UMLS CUI [2,1])
C0205474 (UMLS CUI [2,2])
C0042870 (UMLS CUI [3])
C0020502 (UMLS CUI [4])
C0020626 (UMLS CUI [5])
C0029401 (UMLS CUI [6])
Exclusion Criteria | Thyroid Disease Uncontrolled | Cushing's disease | Pituitary Diseases
Item
no uncontrolled thyroid disease, cushing disease, or other pituitary diseases
boolean
C0680251 (UMLS CUI [1])
C0040128 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0221406 (UMLS CUI [3])
C0032002 (UMLS CUI [4])
Exclusion Criteria | Bone Diseases | Osteomalacia | Osteogenesis Imperfecta
Item
no other bone disease (including osteomalacia or osteogenesis imperfecta)
boolean
C0680251 (UMLS CUI [1])
C0005940 (UMLS CUI [2])
C0029442 (UMLS CUI [3])
C0029434 (UMLS CUI [4])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
ID.12
Item
see disease characteristics
boolean
Exclusion Criteria | Diphosphonates | Bone disorder therapy | Parathyroid hormone therapy | Strontium
Item
at least 6 months since prior and no concurrent bisphosphonate therapy (or other bone therapies such as pth or strontium)
boolean
C0680251 (UMLS CUI [1])
C0012544 (UMLS CUI [2])
C0872270 (UMLS CUI [3])
C3839506 (UMLS CUI [4])
C0038467 (UMLS CUI [5])
Glucocorticoids | Prednisone Dose | Equivalent
Item
at least 6 months since prior glucocorticoid (> 5 mg prednisone or equivalent) for > 1 month
boolean
C0017710 (UMLS CUI [1])
C0032952 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205163 (UMLS CUI [3])
Anticonvulsants
Item
at least 12 months since prior anticonvulsants
boolean
C0003286 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial